LETAIRIS

ambrisentan · Gilead Sciences, Inc.

Drug timelines are a Plus or Pro feature.

53 regulatory and trial events tracked for LETAIRIS, covering 2007-06-15 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome [Phase 2]